The plug is pulled on a deal with J&J, and Fate swings the axe over its staff and NK cell pipeline.
Evaluate Vantage's coverage of the Ash 2022 congress.
Meanwhile, there was bad blood between cell therapy players and their investors.
Affimed investors find that what goes up must come down, though the stock owes only part of its fall to an Ash presentation.
In oncology settings outside multiple myeloma investors have picked two early winners.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.